Mitochondria Dysfunction and Neuroinflammation in Neurodegeneration: Who Comes First?

Antioxidants (Basel). 2024 Feb 16;13(2):240. doi: 10.3390/antiox13020240.

Abstract

Neurodegenerative diseases (NDs) encompass an assorted array of disorders such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis, each characterised by distinct clinical manifestations and underlying pathological mechanisms. While some cases have a genetic basis, many NDs occur sporadically. Despite their differences, these diseases commonly feature chronic neuroinflammation as a hallmark. Consensus has recently been reached on the possibility that mitochondria dysfunction and protein aggregation can mutually contribute to the activation of neuroinflammatory response and thus to the onset and progression of these disorders. In the present review, we discuss the contribution of mitochondria dysfunction and neuroinflammation to the aetiology and progression of NDs, highlighting the possibility that new potential therapeutic targets can be identified to tackle neurodegenerative processes and alleviate the progression of these pathologies.

Keywords: Alzheimer’s disease; Parkinson’s disease; amyotrophic lateral sclerosis; inflammasome; mitochondrial dysfunction; neurodegeneration; oxidative stress.

Publication types

  • Review

Grants and funding

Work in the authors’ laboratory was funded by grants from the Ministry of University and Research (PRIN2017 to T.C. and PRIN2022 no. 20223ABZ82 to M.B.) and from the Università degli Studi di Padova (STARS Consolidator Grant 2019 to T.C., Progetto di Ateneo 2023 no. CALI_BIRD23_01 to T.C.) and from the European Union—Next-Generation EU (PRIN2022 no 20223ABZ82 to M.B and PNRR—CN3 National Center for Gene Therapy and Drugs based on RNA Technology to M.B. and T.C. no. CN00000041 (2022–26)).